These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25643984)

  • 1. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival with bevacizumab in advanced cervical cancer.
    Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
    Eskander RN; Tewari KS
    Curr Opin Obstet Gynecol; 2014 Aug; 26(4):314-21. PubMed ID: 24979076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing paradigms in the systemic treatment of advanced cervical cancer.
    Pfaendler KS; Tewari KS
    Am J Obstet Gynecol; 2016 Jan; 214(1):22-30. PubMed ID: 26212178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
    Tewari KS; Monk BJ
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):108-15. PubMed ID: 20386532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
    Eskander RN; Tewari KS
    Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
    Phippen NT; Leath CA; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2015 Jan; 136(1):43-7. PubMed ID: 25448456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
    Seol HJ; Ulak R; Ki KD; Lee JM
    Tohoku J Exp Med; 2014 Apr; 232(4):269-76. PubMed ID: 24695215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in paclitaxel combinations for treating cervical cancer.
    Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
    Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
    Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
    Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in cervical cancer pharmacotherapies.
    Markman M
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [VEGF--targeted therapy for the treatment of cervical cancer --literature review].
    Salomon-Perzyńska M; Perzyński A; Rembielak-Stawecka B; Michalski B; Skrzypulec-Plinta V
    Ginekol Pol; 2014 Jun; 85(6):461-5. PubMed ID: 25029813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
    Chase D; Huang HQ; Monk BJ; Ramondetta LM; Penson RT; Gil K; Landrum LM; Leitao M; Oaknin A; Huh WK; Pulaski HL; Robison K; Guntupalli SR; Richardson D; Salani R; Sill MW; Wenzel LB; Tewari KS
    Int J Gynecol Cancer; 2020 May; 30(5):596-601. PubMed ID: 32114513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.